Skip to main content



11-21-2017 | Prevention | News

Oral insulin fails to delay type 1 diabetes in high-risk population

Giving daily oral insulin to high-risk relatives of patients with type 1 diabetes did not delay the onset of the condition in the Type 1 Diabetes TrialNet Oral Insulin Study, although the investigators say that doubts surrounding the dose of insulin used means the case is not yet closed.

11-07-2017 | Pregnancy | News

October Cochrane review round-up

The two diabetes-related Cochrane reviews published in October focused on diabetes during pregnancy; the first covered different methods of glucose monitoring, while the second compared oral antidiabetic agents with insulin, with both concluding that better quality research is needed to draw firm conclusions.

10-18-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Read more

Related topics





11-08-2017 | Long-acting insulins | Editorial | Article

Longer-acting basal insulin analogs: What, how, why, when, and who?

Advisory Board member and pharmacist, Josh Neumiller, presents a practical guide to support clinical decision-making in the initiation and titration of U-300 insulin glargine and insulin degludec.

11-25-2016 | Devices and technology | Editorial | Article

Choosing an insulin delivery device

A process of shared and informed decision-making, facilitated by demonstration, helps ensure that the right delivery device is chosen and prescribed for persons who require insulin.

In depth

03-21-2017 | Adolescents | Feature | Article

Adolescents: A challenging age group

Professor Moshe Phillip tells medwireNews why he believes the artificial pancreas will be of particular benefit for adolescents and young adults with type 1 diabetes.

Journal articles and book chapters

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y

10-05-2017 | Hypoglycemia | Review | Article

A systematic approach for the prevention and reduction of hypoglycemia in hospitalized patients

This review highlights approaches to predict and prevent inpatient hypoglycemia focusing on the development of overlapping procedures that allow safe glycemic management to occur at all levels of the institution.

Cruz P, Blackburn MC, Tobin GS. Curr Diab Rep 2017;17:117. doi:10.1007/s11892-017-0934-8

09-14-2017 | Inpatient diabetes | Review | Article

Management of type 1 diabetes in the hospital setting

This review provides practical recommendations for the management of medical and surgical patients with type 1 diabetes admitted to critical and non-critical care settings.

Mendez CE, Umpierrez GE. Curr Diab Rep 2017;17:98. doi:10.1007/s11892-017-0919-7

In practice

05-08-2017 | Type 1 diabetes | Review | Article

A practical review of C-Peptide testing in diabetes

Leighton et al. offer a rationale for the practical and pragmatic use of c-peptide testing to guide the clinical management of individuals with diabetes.

Leighton E, Sainsbury CA, & Jones GC. Diabetes Ther 2017; 8: 475–487. doi:10.1007/s13300-017-0265-4

09-10-2016 | Insulin | Book chapter | Article

Practical aspects of insulin therapy

An overview of the practical considerations and common complications associated with insulin use, including advice for insulin management during exercise, fasting, travel, and driving.

W Crasto, J Jarvis, & MJ Davies. In: Handbook of Insulin Therapies. London, UK: Springer, 2016. doi:10.1007/978-3-319-10939-8_6

Case reports

03-23-2017 | Insulin | Case report | Article

Type III hypersensitivity reaction to subcutaneous insulin preparations in a type 1 diabetic

How would you approach the  case of a 23-year-old diabetic female who developed a type III hypersensitivity reaction to multiple formulations of subcutaneous insulin?

Murray BR et al. J Gen Intern Med 2017; 32: 841–845. doi:10.1007/s11606-017-4037-7

image credits